Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : MRTX crawled time : 20:00 save search
Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)
Published: 2023-10-17 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.04%
H: 0.35%
C: -0.53%
lung cancer cell results
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Published: 2023-09-05 (Crawled : 20:00) - prnewswire.com
MS | News 0 d | $92.09 1.58% 0.01% 7.3M
|
Finance
|
| O: -1.87%
H: 0.0%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.36%
H: 0.86%
C: -1.17%
nasdaq grant therapeutics
Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
Published: 2023-08-29 (Crawled : 20:00) - prnewswire.com
MS | News 0 d | $92.09 1.58% 0.01% 7.3M
|
Finance
|
| O: 1.44%
H: 0.0%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.69%
H: 1.04%
C: 1.01%
conference global therapeutics
Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer
Published: 2023-08-21 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.5%
H: 1.29%
C: -1.02%
lung conference world cancer results study
Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Published: 2023-08-11 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
| Email alert
Add to watchlist
offering therapeutics
Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director
Published: 2023-06-23 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
| Email alert
Add to watchlist
therapeutics
Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting
Published: 2023-05-30 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.43%
H: 2.55%
C: -0.27%
krasg12 asco tumors treatment meeting potential
Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®
Published: 2023-05-24 (Crawled : 20:00) - prnewswire.com
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.81%
H: 0.32%
C: -0.59%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -6.18%
H: 0.0%
C: -6.64%
opdivo update sapphire therapeutics study
Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates
Published: 2023-05-09 (Crawled : 20:00) - globenewswire.com
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: -0.21%
H: 0.32%
C: -0.07%
ZLAB | $14.97 6.4% 6.01% 460K
|
Health Technology
|
| O: 4.89%
H: 6.5%
C: 1.13%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.17%
H: 0.07%
C: -0.17%
NVCR | $11.82 -2.23% -2.28% 810K
|
Health Technology
|
| O: 1.11%
H: 1.89%
C: 0.97%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -2.41%
H: 5.41%
C: 3.75%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 1.07%
H: 1.21%
C: 0.62%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 0.29%
H: 0.07%
C: -1.6%
BPMC | $90.69 4.42% 4.23% 780K
|
Health Technology
|
| O: 1.36%
H: 0.13%
C: -1.89%
results
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Published: 2023-05-05 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
| Email alert
Add to watchlist
nasdaq grant therapeutics
Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs
Published: 2023-04-03 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.85%
H: 0.21%
C: -4.26%
research
First Phase Results of MYLUNG Consortium Provide Historical View of Biomarker Testing Patterns and Identify Data Gaps for Ongoing Prospective Research
Published: 2021-06-04 (Crawled : 20:00) - biospace.com/
MCK | $527.32 0.47% 0.0% 890K
|
Distribution Services
|
| O: 0.27%
H: 0.48%
C: 0.29%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: 0.04%
H: 0.82%
C: -0.38%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 3.38%
H: 1.58%
C: -0.87%
ongoing test results research biomarkers
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.